- Home
- MKZR vs CLDI Comparison
MKZR vs CLDI Comparison
Compare MKZR & CLDI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MKZR
- CLDI
- Stock Information
- Founded
- MKZR 2012
- CLDI 2014
- Country
- MKZR United States
- CLDI United States
- Employees
- MKZR N/A
- CLDI N/A
- Industry
- MKZR
- CLDI Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- MKZR
- CLDI Health Care
- Exchange
- MKZR Nasdaq
- CLDI Nasdaq
- Market Cap
- MKZR 10.3M
- CLDI 10.2M
- IPO Year
- MKZR N/A
- CLDI N/A
- Fundamental
- Price
- MKZR $0.63
- CLDI $0.73
- Analyst Decision
- MKZR
- CLDI
- Analyst Count
- MKZR 0
- CLDI 0
- Target Price
- MKZR N/A
- CLDI N/A
- AVG Volume (30 Days)
- MKZR 536.4K
- CLDI 41.8M
- Earning Date
- MKZR 08-11-2025
- CLDI 08-12-2025
- Dividend Yield
- MKZR 55.53%
- CLDI N/A
- EPS Growth
- MKZR N/A
- CLDI N/A
- EPS
- MKZR N/A
- CLDI N/A
- Revenue
- MKZR $23,037,348.00
- CLDI N/A
- Revenue This Year
- MKZR N/A
- CLDI N/A
- Revenue Next Year
- MKZR N/A
- CLDI N/A
- P/E Ratio
- MKZR N/A
- CLDI N/A
- Revenue Growth
- MKZR 52.64
- CLDI N/A
- 52 Week Low
- MKZR $0.60
- CLDI $0.20
- 52 Week High
- MKZR $5.50
- CLDI $3.89
- Technical
- Relative Strength Index (RSI)
- MKZR N/A
- CLDI 61.42
- Support Level
- MKZR N/A
- CLDI $0.47
- Resistance Level
- MKZR N/A
- CLDI $0.82
- Average True Range (ATR)
- MKZR 0.00
- CLDI 0.19
- MACD
- MKZR 0.00
- CLDI 0.02
- Stochastic Oscillator
- MKZR 0.00
- CLDI 36.03
About MKZR MacKenzie Realty Capital Inc.
Mackenzie Realty Capital Inc is a company which is a Real estate investment trust (REIT). The company has one reportable segment, income-producing real estate properties which consists of activities related to investing in real estate.
About CLDI Calidi Biotherapeutics Inc.
Calidi Biotherapeutics Inc is a clinical-stage immuno-oncology company with technology designed to arm the immune system to fight cancer. The Company's stem cell-based platforms utilize potent allogeneic stem cells capable of carrying payloads of oncolytic viruses for use in a many oncology indications, including high-grade gliomas and solid tumors. Its products include CLD-101 for Recurrent HGG; CLD-201 for Solid Tumors, and CLD-400 for certain lung cancer and Metastatic Solid Tumors. In addition to its pipeline products, the Company's is also engaged in discovery research of CLD-301 (AAA) for tumor Indications.